BGB-10188 is under clinical development by BeiGene and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Renal Cell Carcinoma have a 29% phase transition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback